BL-M24D1
Phase 1Small molecule
BL-M24D1 is one of 131 small molecule programs targeting Gastrointestinal Tumors. It is currently in Phase 1.
4
Indications
4
Total Trials
4
Active Trials
130
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Opdualag
Bristol-Myers SquibbPhase 3
Platinum
Bristol-Myers SquibbPhase 3
YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
BL-M24D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastrointestinal Tumors1 trial
Non-Small Cell Lung Cancer1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BL-M24D1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details